ADMA Biologics, Inc. (ADMA) |
|
3.58 0.04 (1.13%)
|
09-29 16:00 |
|
Open: |
3.56 |
Pre. Close: |
3.54 |
|
High:
|
3.63 |
Low:
|
3.54 |
|
Volume:
|
1,768,857 |
Market Cap:
|
805(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 8:14:13 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.43 One year: 4.69 |
| Support: |
Support1: 3.43 Support2: 2.85 |
| Resistance: |
Resistance1: 3.79 Resistance2: 4.01 |
| Pivot: |
3.63  |
| Moving Average: |
MA(5): 3.54 MA(20): 3.7
MA(100): 3.88 MA(250): 3.52 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 26.1 %D(3): 22.4 |
| RSI: |
RSI(14): 40.5 |
| 52-week: |
High: 4.65 Low: 2.41 |
| Average Vol(K): |
3-Month: 2,136 (K) 10-Days: 1,394 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADMA ] has closed above bottom band by 36.8%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.63 - 3.65 |
3.65 - 3.67 |
|
Low:
|
3.5 - 3.52 |
3.52 - 3.53 |
|
Close:
|
3.55 - 3.58 |
3.58 - 3.61 |
|
Company Description |
|
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. |
Headline News |
Fri, 29 Sep 2023
ADMA Biologics, Inc. (NASDAQ:ADMA) Receives Consensus Rating ... - MarketBeat
Wed, 27 Sep 2023
Coal Mining Market size to increase by USD 82.39 billion from 2022 to 2027, Adani Group, Alpha Metallurgical Resources Inc., Anglo American plc, and more among key companies - Technavio - Yahoo Finance
Mon, 25 Sep 2023
Global Plasma Fractionation Market Size Projected to Reach USD ... - GlobeNewswire
Mon, 18 Sep 2023
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by First ... - MarketBeat
Sun, 10 Sep 2023
ADMA Biologics (NASDAQ:ADMA) Downgraded to "Sell" at ... - MarketBeat
Thu, 31 Aug 2023
Will ADMA Biologics Inc (ADMA) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
225 (M) |
| Shares Float |
209 (M) |
|
% Held by Insiders
|
2.5 (%) |
|
% Held by Institutions
|
77.7 (%) |
|
Shares Short
|
8,860 (K) |
|
Shares Short P.Month
|
8,310 (K) |
Stock Financials |
|
EPS
|
-0.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.64 |
|
Profit Margin (%)
|
-19.4 |
|
Operating Margin (%)
|
-6.7 |
|
Return on Assets (ttm)
|
-2.8 |
|
Return on Equity (ttm)
|
-30.9 |
|
Qtrly Rev. Growth
|
77.3 |
|
Gross Profit (p.s.)
|
0.15 |
|
Sales Per Share
|
0.92 |
|
EBITDA (p.s.)
|
-0.03 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-41 (M) |
|
Levered Free Cash Flow
|
-38 (M) |
Stock Valuations |
|
PE Ratio
|
-18.85 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
5.5 |
|
Price to Sales
|
3.86 |
|
Price to Cash Flow
|
-19.43 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
